CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

202293 citationsJournal Articlebronze Open Access

Authors

Sarah M. Larson · University of California, Los Angeles

Christopher M. Walthers · University of California, Los Angeles

Brenda Ji · University of California, Los Angeles

Sanaz N. Ghafouri · University of California, Los Angeles

Jacob Naparstek · Parker Institute for Cancer Immunotherapy

Jacqueline Trent · Parker Institute for Cancer Immunotherapy

Jia Ming Chen

Abstract

Autologous CD19/CD20 bispecific CAR-T cell therapy generated from TN/MEM cells for patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and demonstrates strong efficacy (90% ORR, 70% CR rate) in a first-in-human, phase I dose-escalation trial. This article is highlighted in the In This Issue feature, p. 517.

Topics & Keywords

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Discovery

Volume 13, Issue 3, pp. 580-597

DOI: 10.1158/2159-8290.cd-22-0964

Field-Weighted Citation Impact: 8.59